866-997-4948(US-Canada Toll Free)

Neisseria meningitidis Infections-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 78 Pages

Neisseria meningitidis Infections-Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Neisseria meningitidis Infections-Pipeline Review, H2 2017, provides an overview of the Neisseria meningitidis Infections (Infectious Disease) pipeline landscape.

Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and dust storms and concomitant respiratory infections.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Neisseria meningitidis Infections-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neisseria meningitidis Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 2, 3, 2, 9 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 5 and 1 molecules, respectively.

Neisseria meningitidis Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neisseria meningitidis Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neisseria meningitidis Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neisseria meningitidis Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neisseria meningitidis Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Neisseria meningitidis Infections-Overview 6
Neisseria meningitidis Infections-Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 13
Neisseria meningitidis Infections-Therapeutics Assessment 14
Assessment by Target 14
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Neisseria meningitidis Infections-Companies Involved in Therapeutics Development 22
Beijing Minhai Biotechnology Co Ltd 22
Biological E Ltd 22
China National Pharmaceutical Group Corp 22
Chongqing Zhifei Biological Products Co Ltd 23
GlaxoSmithKline Plc 23
ImmunoBiology Ltd 24
JN-International Medical Corp 24
MGB Biopharma Ltd 25
Pfizer Inc 25
Sanofi Pasteur SA 26
Serum Institute of India Ltd 26
Wellstat Vaccines LLC 26
Neisseria meningitidis Infections-Drug Profiles 28
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine-Drug Profile 28
(Haemophilus influenzae [serotype B] + meningococcal) vaccine-Drug Profile 29
(Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine-Drug Profile 30
(meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine-Drug Profile 31
MenBioVax-Drug Profile 32
meningococcal (tetravalent) vaccine-Drug Profile 33
meningococcal [serotype B] vaccine-Drug Profile 34
meningococcal [serotype B] vaccine-Drug Profile 35
meningococcal [serotype B] vaccine-Drug Profile 36
meningococcal [serotype B] vaccine-Drug Profile 37
meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine-Drug Profile 38
meningococcal [serotypes A, B, C] vaccine-Drug Profile 40
meningococcal [serotypes A, C, W, Y] vaccine-Drug Profile 41
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine-Drug Profile 42
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine-Drug Profile 44
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine-Drug Profile 45
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine-Drug Profile 46
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2-Drug Profile 47
meningococcal [serotypes A, C, W-135, Y] vaccine-Drug Profile 48
meningococcal [serotypes A, C, W135] vaccine-Drug Profile 49
meningococcal [serotypes C, Y] vaccine-Drug Profile 50
meningococcal [strain C2135] vaccine-Drug Profile 51
meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine-Drug Profile 52
meningococcal vaccine-Drug Profile 53
meningococcal vaccine 2-Drug Profile 54
MGBBP-3-Drug Profile 55
NCL-195-Drug Profile 58
Neisseria meningitidis [serotype B] vaccine-Drug Profile 59
Neisseria meningitidis [serotype B] vaccine-Drug Profile 60
PF-06886992-Drug Profile 61
TP-10-Drug Profile 62
Neisseria meningitidis Infections-Dormant Projects 63
Neisseria meningitidis Infections-Discontinued Products 65
Neisseria meningitidis Infections-Product Development Milestones 66
Featured News & Press Releases 66
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 75
Disclaimer 76

List of Tables
Number of Products under Development for Neisseria meningitidis Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Neisseria meningitidis Infections-Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017
Neisseria meningitidis Infections-Pipeline by Biological E Ltd, H2 2017
Neisseria meningitidis Infections-Pipeline by China National Pharmaceutical Group Corp, H2 2017
Neisseria meningitidis Infections-Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2017
Neisseria meningitidis Infections-Pipeline by GlaxoSmithKline Plc, H2 2017
Neisseria meningitidis Infections-Pipeline by ImmunoBiology Ltd, H2 2017
Neisseria meningitidis Infections-Pipeline by JN-International Medical Corp, H2 2017
Neisseria meningitidis Infections-Pipeline by MGB Biopharma Ltd, H2 2017
Neisseria meningitidis Infections-Pipeline by Pfizer Inc, H2 2017
Neisseria meningitidis Infections-Pipeline by Sanofi Pasteur SA, H2 2017
Neisseria meningitidis Infections-Pipeline by Serum Institute of India Ltd, H2 2017
Neisseria meningitidis Infections-Pipeline by Wellstat Vaccines LLC, H2 2017
Neisseria meningitidis Infections-Dormant Projects, H2 2017
Neisseria meningitidis Infections-Dormant Projects, H2 2017 (Contd..1), H2 2017
Neisseria meningitidis Infections-Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Neisseria meningitidis Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *